Posts

Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout

on

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on

Merck & Co.'s Keytruda Posts $8B in Q1 2026 as Qlex Picks Up Steam

on

Bicycle Therapeutics Downsizes by 30% After Deprioritizing Lead Cancer Drug Program

on

Ipsen Withdraws Cancer Drug Tazverik from Market Due to Secondary Blood Cancer Risks

on

Pfizer's 2026 Guidance: Cancer Drug Setback and Obesity Progress Amid Earnings

on

Formation Bio Eyes Abivax-Like Success with Chinese Drug Licensing Deal Targeting Same Mechanism

on

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio's Pan-KRAS Inhibitor JAB-23E73

on

German Court Blocks Merck's Subcutaneous Keytruda Over Patent Dispute with Halozyme

on

Replimune's Shares Plunge After FDA Rejects Melanoma Drug Application

on

Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS

on

Patent Dispute Erupts Over Merck's Injectable Keytruda

on

FDA Issues Untitled Letter to NJ Drugmaker for Misleading Cancer Drug Claims at Conference

on

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts

on